Bruno Angelici - Novo Nordisk Independent Director

NVO Stock  USD 128.40  0.35  0.27%   

Director

Mr. Bruno F. J. Angelici has served as Independent Member of the Board of Directors of Novo Nordisk AS since March 23, 2011. He was Member of the Nomination Committee of the Company since April 2013. He was Executive Vice President of AstraZeneca, with PL responsibility for Europe, Japan, Asia Pacific, Latin America, Middle East and Africa from 2001 until 2009. In 1998, he was appointed President of Zeneca, Japan. Previously, from 1989, he was President of Zeneca, France, having joined from Baxter International, where he held various management positions from 1978 to 1989. He is Member of the Board of Directors of Smiths Group plc and Wolters Kluwer, as well as Chairman of the Board of Vectura Group plc. Additionally, he is Member of the Global Advisory Board at Takeda Pharmaceutical Company Limited, Japan. He has global experience with two companies in the fields of pharmaceuticals and medical devices, as well as knowledge of strategy, sales, marketing and governance of main companies. He holds a Bachelor of Arts degree in Business Administration from Ecole Superieure de Commerce Reims from 1971. He graduated in Law from Universite de Reims Champagne Ardenne in 1973. In addition, he has a MBA degree from Kellogg School of Management at NorthWestern University from 1978 and an AMP from Harvard Business School from 1993, both in the United States. since 2011.
Age 68
Tenure 13 years
Professional MarksMBA
Address Novo Alle 1, Bagsvaerd, Denmark, 2880
Phone45 44 44 88 88
Webhttps://www.novonordisk.com

Novo Nordisk Management Efficiency

The company has Return on Asset of 0.2339 % which means that on every $100 spent on assets, it made $0.2339 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.8807 %, implying that it generated $0.8807 on every 100 dollars invested. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Novo Nordisk's Return On Capital Employed is very stable compared to the past year. As of the 29th of March 2024, Return On Equity is likely to grow to 0.82, while Return On Assets are likely to drop 0.14. At this time, Novo Nordisk's Total Assets are very stable compared to the past year. As of the 29th of March 2024, Non Current Assets Total is likely to grow to about 183.6 B, while Non Currrent Assets Other are likely to drop about 1.4 B.
The company has 27.01 B in debt with debt to equity (D/E) ratio of 0.34, which is OK given its current industry classification. Novo Nordisk AS has a current ratio of 0.9, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist Novo Nordisk until it has trouble settling it off, either with new capital or with free cash flow. So, Novo Nordisk's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novo Nordisk AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novo to invest in growth at high rates of return. When we think about Novo Nordisk's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Donald KutynaGriffon
84
Edson NobreBraskem SA Class
69
Patrick FaironBraskem SA Class
59
Pedro SousaBraskem SA Class
45
Luiz MendoncaBraskem SA Class
54
Ricardo BaldinBraskem SA Class
63
Blaine FoggGriffon
77
Kenneth HartwickMYR Group
55
Michael KaufmanSkyline
48
Alfredo TellecheaBraskem SA Class
58
John SchauermanMYR Group
60
John FirthSkyline
60
Martin SussmanGriffon
76
Newton SouzaBraskem SA Class
63
Daniel VillarBraskem SA Class
42
Elaine WedralSensient Technologies
77
Jennifer LowryMYR Group
49
Victor RenuartGriffon
71
Donald LandrySensient Technologies
66
William LawsonSkyline
79
James CroftSensient Technologies
76
Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Novo Nordisk is traded on New York Stock Exchange in the United States. Novo Nordisk AS (NVO) is traded on New York Stock Exchange in USA. It is located in Novo Alle 1, Bagsvaerd, Denmark, 2880 and employs 63,370 people. Novo Nordisk is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Novo Nordisk AS Leadership Team

Elected by the shareholders, the Novo Nordisk's board of directors comprises two types of representatives: Novo Nordisk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novo. The board's role is to monitor Novo Nordisk's management team and ensure that shareholders' interests are well served. Novo Nordisk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novo Nordisk's outside directors are responsible for providing unbiased perspectives on the board's policies.
Soeren Pedersen, Director, Employee Representative
Doug Langa, Senior Vice President Head of North America Operations and Presidentident of Novo Nordisk Inc.
Jakob Riis, Executive VP of China, Pacific and Marketing and Member of Executive Management
Kasim Kutay, Director
Jesper Brandgaard, CFO, Executive Vice President
Sylvie Gregoire, Independent Director
Mette Jensen, Director, Employee Representative
Mary Szela, Director
Jerzy Gruhn, Executive Vice President Europe
Douglas Langa, Executive Vice President - North America Operations
Eivind Kolding, Director
Kasper Poulsen, Head of Investor Relations, Corporate Vice President
Thomas Rantzau, Director, Employee Representative
Lars Jorgensen, CEO President
Daniel Bohsen, CVP Relations
Henrik Poulsen, Director
Karsten Knudsen, Chief Financial Officer, Executive Vice President
Lars Joergensen, President, Chief Executive Officer
Helge Lund, Independent Chairman of the Board
Martin Lange, Executive Vice President - Development
Maziar Doustdar, Executive Vice President - International Operations
Brian Daniels, Independent Director
Goran Ando, Chairman of the Board
Martin Mackay, Independent Director
Jeppe Christiansen, Vice Chairman of the Board
Bruno Angelici, Independent Director
Liselotte Hyveled, Director, Employee Representative
Anne Kverneland, Director, Employee Representative
Tania Sabroe, Executive Board
Kaare Schultz, President COO
Liz Hewitt, Independent Director
Jesper Hoeiland, Executive Vice President US
Ludovic Helfgott, Executive Vice President of Biopharm
Camilla Sylvest, Executive Vice President - Commercial Strategy and Corporate Affairs
Mads Thomsen, Chief Science Officer, Executive VP and Member of Executive Management
Andreas Fibig, Independent Director
Monique Carter, Executive Vice President - People and Organisation
Peter Ankersen, Corporate Vice President & Head of Investor Relations
Laurence Debroux, Independent Director
Lars Soerensen, CEO
Marcus Schindler, Executive Vice President - Research and Early Development, Chief Scientific Officer
Stig Stroebaek, Director, Employee Representative
Henrik Wulff, Executive Vice President - Product Supply Quality and IT
Thomas Koestler, Independent Director
Lars Green, Executive Vice President Business Services & Compliance

Novo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novo Nordisk a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Novo Nordisk Investors Sentiment

The influence of Novo Nordisk's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novo. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novo Nordisk's public news can be used to forecast risks associated with an investment in Novo. The trend in average sentiment can be used to explain how an investor holding Novo can time the market purely based on public headlines and social activities around Novo Nordisk AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novo Nordisk's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novo Nordisk's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novo Nordisk's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novo Nordisk.

Novo Nordisk Implied Volatility

    
  26.87  
Novo Nordisk's implied volatility exposes the market's sentiment of Novo Nordisk AS stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Novo Nordisk's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Novo Nordisk stock will not fluctuate a lot when Novo Nordisk's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novo Nordisk in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novo Nordisk's short interest history, or implied volatility extrapolated from Novo Nordisk options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for Novo Stock analysis

When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Bonds Directory
Find actively traded corporate debentures issued by US companies
Stocks Directory
Find actively traded stocks across global markets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.631
Dividend Share
9.4
Earnings Share
2.7
Revenue Per Share
51.812
Quarterly Revenue Growth
0.37
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.